Podcasts about risk factors

Drs Milner, Dalal, and Ligon discuss hematopoietic stem cell transplant in children with severe aplastic anemia, graft failure risk factors in children receiving hematopoietic cell transplant for non-malignant disorders, and the use of mediports for CAR T-cell infusion.

One of the biggest expenses we face is health insurance, and many have turned to medical cost sharing programs & ministries as an alternative to traditional insurance. Clark explains the inherent risks involved with these health care co-ops. Also, a follow up on the Kia and Hyundai theft problems causing auto insurance cancellations for some owners. There are remedies from the automaker which owners of the affected models need to know about.  Health Coverage Co-op Warning: Segment 1 Ask Clark: Segment 2 Kia and Hyundai Theft Solutions: Segment 3 Ask Clark: Segment 4 Mentioned on the show A Christian Ministry Promised An Obamacare Alternative. The FBI Says Its Leaders Pocketed $4 Million And Left Members With Thousands In Unpaid Medical Bills A Christian Health Nonprofit Saddled Thousands With Debt as It Built a Family Empire Including a Pot Farm, a Bank and an Airline 10 Ways To Save on Prescription Drugs What Does a Home Warranty Cover, and Is It Worth The Money? Here Are Your Home Warranty Horror Stories When Is the Best Time To Collect Social Security? AARP's free Social Security calculator helps you maximize your benefits Maximize My Social Security: Calculate Your Highest Benefits Kia might owe you money. Here's how to check Hyundai releases anti-theft software upgrade for 4 million cars after insurers drop some models   CUNA.org - Find a Credit Union Clark.com resources Episode transcripts Clark.com daily money newsletter Consumer Action Center Free Helpline: 636-492-5275 Learn more about your ad choices: megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

In her Expert Commentary, Dr. Melanie Ward from West Virginia University's Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of disease progression and disability.Join us for this podcast as Dr. Ward explains how these findings can affect clinical practice to improve overall care of individuals with MS. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Genetic counseling is more than just testing a patient for specific diseases. Counselors like Kevin Sweet and Colleen Jodarski become health investigators, sifting through a patient's family history to compile a complete look at their risk factors. Our experts explain how to know if you need to see a genetic counselor. Learn More: https://radiohealthjournal.org/a-look-at-the-rising-field-of-genetic-counseling

If you are interested in learning about the various risk factors that can impact cognitive health and potentially lead to cognitive decline, this episode is for you. The mnemonic "Bright Minds" provides an easy-to-remember framework for understanding and addressing these risk factors, and I provide detailed explanations of each one. Episode Resources on the blog at https://rawfoodmealplanner.com // HOST Samantha Salmon Certified Integrative Nutrition Health Coach and Brain Health Licensed Trainer The information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the food and drug administration, or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2023

For most of the past century, more women than men have died from cardiovascular disease, heart attacks, and stroke… …and as many as half of the women in developed countries, including the US, will die of these almost entirely-preventable conditions.  Yet it is still considered to be primarily a male problem… But why? Catch today's episode for all the science behind why women are more prone to heart disease, as well as simple steps you can take to prevent it–and learn: What your genetics, lifestyle, and hormones are telling you How sleep, stress, and blood sugar play into the equation 10 unique risk factors for women  4 simple steps for preventing heart disease      8 blood sugar hacks to fix your metabolic health now  Mentioned in this Episode: Gluco Support – The Blood Sugar-Balancer  90-Day Metabolism Makeover Program – Work one-on-one with me to heal your body! Additional Resources: 451: Why Do Women Have a Higher Cardiometabolic Mortality Rate Than Men? #379: 7 Effective Herbs for Stopping a Blood Sugar Spike and Addressing Poor Metabolic Health #494: How to Work One-on-one with Me in My New Metabolism Makeover Coaching Program 3 Reasons it's Critical to have Metabolic Flexibility

Should I Only Eat Nuts And Seeds That Are Raw? Baxter Montgomery, MD • https://montgomeryheart.com/ • Book - The Food Prescription for Better Health: A Cardiologists Proven Method to Reverse Heart Disease, Diabetes, Obesity, and Other Chronic Illnesses Naturally! #BaxterMontgomery#Cardiologist #PlantBasedDiet #WholeFood #Cholesterol Dr. Baxter D. Montgomery is an Author and Board-Certified Cardiologist with years of experience in the latest medical practices and nutritional health.  His Book, The Food Prescription for Better Health will help you find your prescription for optimal health in the foods you eat. For years Dr. Baxter Montgomery, has been helping patients overcome heart disease and other chronic illnesses through nutritional excellence. Now you can benefit from his knowledge and experience. The Book Features:• Outlines the poor health condition of Americans• Provides a detailed description of how the body works• Tells the real story of what healthy food is, dispelling many myths• Describes how proper nutrition is important for optimal health• Provides a step-by-step approach to reverse your health problems using nutrition• Shows scientific evidence for the efficacy of the program Dr. Montgomery is a Clinical Assistant Professor of Medicine in the Division of Cardiology at the University of Texas in Houston, a Fellow of the American College of Cardiology (FACC) and the founder and president of the Houston Cardiac Association (HCA).  Having seen many patients suffer the consequences of chronic heart disease, Dr. Montgomery founded the Montgomery Heart & Wellness Center in 2006 with the mission to reverse and prevent life-threatening illnesses. Located in Houston, Texas, The Montgomery Heart & Wellness Center is a state-of-the-art wellness facility complete with all the technology and resources to provide comprehensive medical and wellness care.  Combining his medical practice with a food-driven lifestyle intervention, Dr. Montgomery introduces patients to a novel food classification system that helps reverse chronic conditions such as heart disease, hypertension, obesity and diabetes without medications or surgeries.  He has refined this process over the past 10 years with profound positive results in severely ill patients. In addition to running Montgomery Heart & Wellness, Dr. Montgomery manages arrhythmias and coronary disease, performs angiographies, defibrillator implants and other hospital procedures, and teaches young physicians.  Dr. Montgomery earned his undergraduate degree from Rice University in Houston and his Medical Degree from The University of Texas Medical Branch in Galveston, Texas.  To Contact Dr. Baxter Montgomery Go to  MontgomeryHeart.com Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

In the United States, there are 10 million women with OSTEOPOROSIS and 43 million women with OSTEOPENIA. Most of these women do not know they are at risk for a potential life-changing or even fatal fracture.  My guest is Dr. Kristi Tough DeSapri, an internist with a specialty and expertise in women's bone health. This topic is in 2 parts. If you haven't already, please start with Part 1, Episode 59, which focuses on WHY YOU SHOULD CARE about bone health, RISK FACTORS for osteoporosis, and SCREENING RECOMMENDATIONS.  This episode will focus on PREVENTION and TREATMENT including:  What specific kinds of EXERCISE build bone and why CROSS TRAINING is important The importance of BALANCE Why women with INCONTINENCE and osteoporosis are at exceptionally high risk for fracture If YOGA is good for your bones How to get enough CALCIUM  If supplemental calcium is bad for your HEART Why you should test your VITAMIN D and how much you need If you have low bone mass (OSTEOPENIA) how to prevent further bone loss Why ESTROGEN is beneficial for bones The benefit of RELOXIFEN (Evista™) If HEAVY METALS are beneficial? Options to treat OSTEOPOROSIS Who is at highest risk for FRACTURE When a BONE BUILDING medicine is appropriate When medications, such as bisphosphonates, that PREVENT BONE RESORPTON are appropriate If OSTEONECROSIS of the jaw is something to worry about                                          For More Information   Dr. Tough DeSapri's Website https://boneandbodywh.com Bone Health and Osteoporosis Foundation:  https://www.bonehealthandosteoporosis.org/ Buff Bones:  https://buff-bones.com/ Bone Fit Training: https://www.bonehealthandosteoporosis.org/bonefit-find-a-professional/ Osteoporosis Canada  https://osteoporosis.ca/exercise-recommendations/ Calcium calculator:  https://osteoporosis.ca/calcium-calculator/ Episode 2:Think Your Hot Flashes Can't Kill You? Think Again! Episode 12: Your Muscles on Menopause with Amanda Thebe  Episode 21:  Say Yes! to Testosterone for Women Episode 31 The TRUTH About Hormone Therapy: Does it CAUSE or Does it PREVENT Breast Cancer? Episode 59- Boning Up on Bones: Part 1 with Dr. Kristi Tough DeSapri Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Lauren Streicher, MD is a clinical professor of obstetrics and gynecology at Northwestern University's Feinberg School of Medicine and the founding medical director of the Northwestern Medicine Center for Sexual Medicine and Menopause. She is a certified menopause practitioner of the North American Menopause Society.  Sign up to receive DR. STREICHER'S FREE NEWSLETTER Dr. Streicher is the medical correspondent for Chicago's top-rated news program, the WGN Morning News, and has been seen on The Today Show, Good Morning America, The Oprah Winfrey Show, CNN, NPR, Dr. Radio, Nightline, Fox and Friends, The Steve Harvey Show, CBS This Morning, ABC News Now, NBCNightlyNews,20/20, and World News Tonight. She is an expert source for many magazines and serves on the medical advisory board of The Kinsey Institute, Self Magazine, and Prevention Magazine. She writes a regular column for The Ethel by AARP and Prevention Magazine.  Instagram @DrStreich Twitter @DrStreicher Facebook  @DrStreicher YouTube  DrStreicherTV Books by Lauren Streicher, MD  Slip Sliding Away: Turning Back the Clock on Your Vagina-A gynecologist's guide to eliminating post-menopause dryness and pain Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Sex Rx- Hormones, Health, and Your Best Sex Ever The Essential Guide to Hysterectomy

The Most Common Genetic Risk Factor For Alzheimer's Dale Bredesen, MD • https://www.ahnphealth.com/dr-bredesen.html • Book - End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline #DaleBredesen #Alzheimer's #Dementia #CognitiveDecline Dr. Dale Bredesen'sis an author and internationally-recognized expert in the mechanisms of neurodegenerative diseases, and is a New York Times bestselling author for - The End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline  This book is a groundbreaking plan to prevent and reverse Alzheimer's Disease that fundamentally changes how we understand cognitive decline. Everyone knows someone who has survived cancer, but until now no one knows anyone who has survived Alzheimer's Disease.  In this paradigm shifting book, Dale Bredesen, MD, offers real hope to anyone looking to prevent and even reverse Alzheimer's Disease and cognitive decline.  Revealing that AD is not one condition, as it is currently treated, but three, The End of Alzheimer's outlines 36 metabolic factors (micronutrients, hormone levels, sleep) that can trigger "downsizing" in the brain. The protocol shows us how to rebalance these factors using lifestyle modifications like taking B12, eliminating gluten, or improving oral hygiene. The results are impressive. Of the first ten patients on the protocol, nine displayed significant improvement with 3-6 months; since then the protocol has yielded similar results with hundreds more. Now, The End of Alzheimer's brings new hope to a broad audience of patients, caregivers, physicians, and treatment centers with a fascinating look inside the science and a complete step-by-step plan that fundamentally changes how we treat and even think about AD. Dr. Dale Bredesen's career has been guided by a simple idea: that Alzheimer's as we know it is not just preventable, but reversible. Thanks to a dedicated pursuit of finding the science that makes this a reality, his idea has placed Dr. Bredesen at the vanguard of neurological research, and led to the discoveries that today underlie the ReCode Report. Dr. Bredesen earned his MD from Duke University Medical Center and served as Chief Resident in Neurology at the University of California, San Francisco (UCSF) before joining Nobel laureate Stanley Prusiner's laboratory at UCSF as an NIH Postdoctoral Fellow. He held faculty positions at UCSF, UCLA and the University of California, San Diego. Dr. Bredesen also directed the Program on Aging at the Burnham Institute before joining the Buck Institute in 1998 as founding President and CEO. Dr. Bredesen's research explores previously uncharted territory in explaining the physical mechanism behind the erosion of memory seen in Alzheimer's disease and has opened the door to new approaches to treatment. This work has led to the identification of several new therapeutic processes that are showing remarkableearly results. Dr. Bredesen is a prodigious innovator in medicine, with over thirty patents to his name. Notably, he put much of his finding and research into the 2017 New York Times best-seller The End of Alzheimer's. To Contact Dr Bredesen go to ApolloHealthCo.com Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Drs Short and Reagan discuss risk factors that can contribute to patients' likelihood of developing tumor lysis syndrome, preventive measures for patients most at risk, and the clinical implications of standard treatment options for patients with tumor lysis syndrome.

In this episode, we're discussing the opioid epidemic and its impact on our society. Our guest is Gary Call, a family physician, who shares the emotional and financial cost on individuals and families caused by opioid addiction and overdoses is immense and impacts everyone. We'll also be discussing the latest research on the opioid epidemic, including a study by Stanford researchers led by Dr. Tina Hernandez-Boussard, which aimed to develop a predictive model to identify risk factors for non-opioid users becoming chronic users. The study leveraged a unique research database of millions of de-identified Medicaid paid claims, and the results are both instructive and actionable. Dr. Call will also talk about the importance of translating research from leading academic institutions into real-world use cases that solve important health care problems and how it can help create a more equitable and effective system for all. Tune in to learn more about the opioid epidemic and what we can do to address it. Gary Call is a family physician and health care executive. He shares his story and discusses his KevinMD article, "Think twice before prescribing opioids as a first-line treatment for pain." The Podcast by KevinMD is brought to you by the Nuance Dragon Ambient eXperience. With so many demands on their time, physicians today report record levels of burnout. Burnout is caused by many factors, one of which is clinical documentation. Studies indicate physicians spend two hours documenting care for every hour spent with patients. At Nuance, we are committed to helping physicians do what you love – care for patients – and spend less time on clinical documentation. The Nuance Dragon Ambient eXperience, or DAX for short, is an AI-powered, ambient clinical intelligence solution that automatically captures patient encounters securely and accurately at the point of care. Physicians who use DAX have reported a 50 percent decrease in documentation time and a 70 percent reduction in feelings of burnout, and 83 percent of patients say their physician is more personable and conversational. Rediscover the joy of medicine with clinical documentation that writes itself, all within the EHR. VISIT SPONSOR → https://nuance.com/daxinaction SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RATE AND REVIEW → https://www.kevinmd.com/rate FOLLOW ON INSTAGRAM → https://www.instagram.com/kevinphomd FOLLOW ON TIKTOK → https://www.tiktok.com/@kevinphomd GET CME FOR THIS EPISODE → https://earnc.me/2MuBgX Powered by CMEfy.

Dr. Kendra Wulczyn discusses the results of her study "Incidence and Risk Factors for Pruritus in Patients with Nondialysis CKD," on behalf of her colleagues.

In this episode we chat with special guest, Leslie Flannery, who is a Registered Dietitian specializing in gestational diabetes. We talk about common misconceptions with GD, risk factors, how to prepare for the test, and 3 tips to manage your blood sugar early on in pregnancy (and beyond!). Whether you have GD or not, you'll have some tangible tips to take with you for balanced nutrition in pregnancy. Connect with Leslee on Instagram @gestational.diabetes.nutrition Work with me 1:1 Pre/postnatal Performance Coaching Connect with me on Instagram! @strongmamawellness Learn more about my work on the website

In the United States, there are 10 million women with OSTEOPOROSIS and 43 million women with OSTEOPENIA. Most of these women have no idea that they are at risk for a potentially life-changing or even fatal fracture.  One reason for this lack of concern and lack of awareness is that osteoporosis is usually a “silent disease”. Today, I am going to break that silence. My guest is Dr. Kristi Tough DeSapri, an internist with a specialty and expertise in women's bone health. This topic is in 2 parts. This episode will focus on WHY YOU SHOULD CARE about bone health, RISK FACTORS for osteoporosis, and SCREENING RECOMMENDATIONS. Episode 61, Part 2 will focus on prevention and treatment.  We discuss: Why there is so little awareness of osteoporosis The consequences of osteoporosis Symptoms and early warning signs of bone loss The difference between osteopenia and osteoporosis How common osteoporosis is When someone should get their first screening Risk factors for osteoporosis Why women are more likely to get osteoporosis than men Dr. Kristi Tough DeSapri boneandbodywh.com For more information: Bone Health and Osteoporosis Foundation Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Lauren Streicher, MD is a clinical professor of obstetrics and gynecology at Northwestern University's Feinberg School of Medicine, and the founding medical director of the Northwestern Medicine Center for Sexual Medicine and Menopause. She is a certified menopause practitioner of the North American Menopause Society.  Sign up to receive DR. STREICHER'S FREE NEWSLETTER Dr. Streicher is the medical correspondent for Chicago's top-rated news program, the WGN Morning News, and has been seen on The Today Show, Good Morning America, The Oprah Winfrey Show, CNN, NPR, Dr. Radio, Nightline, Fox and Friends, The Steve Harvey Show, CBS This Morning, ABC News Now, NBCNightlyNews,20/20, and World News Tonight. She is an expert source for many magazines and serves on the medical advisory board of The Kinsey Institute, Self Magazine, and Prevention Magazine. She writes a regular column for The Ethel by AARP and Prevention Magazine.  Instagram @DrStreich Twitter @DrStreicher Facebook  @DrStreicher YouTube  DrStreicherTV Books by Lauren Streicher, MD  Slip Sliding Away: Turning Back the Clock on Your Vagina-A gynecologist's guide to eliminating post-menopause dryness and pain Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Sex Rx- Hormones, Health, and Your Best Sex Ever The Essential Guide to Hysterectomy

Happy Wednesday to you!! Today is the first day of February and that means it is HEART HEALTH month! Heart health holds a special place in my heart (pun intended). My grandpa passed at age 52 from a heart attack and I have to be careful of my heart health and now that I'm over 40...it's that much more important. Did you know one woman in the United States dies from heart disease every minute. The risk increases with age. Let's do what we can NOW to prevent that from being you or someone you love.These are some things that I mention in today's episode that HELP heart health: 1. Salmon - High in omega-3 fatty acids, which can lower LDL (bad) cholesterol and help reduce inflammation.2. Olive Oil - Contains unsaturated fats that can help lower blood pressure and cholesterol.3. Avocados - A good source of monounsaturated fat, which helps reduce the risk of stroke and coronary heart disease.4. Dark Chocolate - Contains flavanols that can help lower blood pressure and reduce inflammation.5. Citrus Fruits - High in vitamin C, which can help reduce inflammation and lower cholesterol.6. Nuts – A good source of protein and healthy fat, nuts can help lower cholesterol and improve heart health...And of course EXERCISE. Try Shakeology here! https://www.teambeachbody.com/shop/us/d/chocolate-plant-based-vegan-shakeology-SHKCHVegan?referringRepID=146964

A recent U.S. study estimated that 9%, or around 278,266, people in Utah will experience an eating disorder sometime during their lives. The Utah Women & Leadership Project with Utah State University highlighted in a recent study multiple factors that put girls and women at risk for eating disorders, including trauma, social media pregnancy, healthcare access, and suicide. Kari spoke to Sarah Boghosian, a clinical assistant professor at Utah State University and a licensed psychologist, about this. She defines eating disorders and explains how they are impacting women and what we can do to help ourselves and our loved ones. Kari, Brooke, David, Elora, and Sarah host Fresh Living on KUTV, which airs on CBS Channel 2 every weekday at 1 pm in Utah. You can follow Fresh Living on all social media platforms @kutvfreshliving and watch our show on YouTube.

Heart disease affects countless women across the globe and is often misunderstood and under-recognized. In honor of the American Heart Association's Go Red for Women campaign, which is later this week, I am so excited to bring to you this interview  Dr. Odayme Quesada. As the director of the Women's Heart Center at Christ Hospital in Cincinnati, she is a preeminent authority in the field of cardiovascular disease in women and the recipient of a million-dollar grant specifically to address women's heart disease and prevention. Tune in to this episode for valuable insight and knowledge about women's heart health and to learn more about the vital work being done to reduce the impact of heart disease in women.What you will learn from this episode:Identifying and understanding the various risk factors for women's heart disease, including high blood pressure, high cholesterol, pre-eclampsia, sedentary lifestyle, and hormonal changesKnowing the early warning signs of heart disease, in women; andUnderstanding the impact of stress and the importance of stress management for heart healthRock Your Red!Join us on National Wear Red Day (Friday, February 3rd) and raise awareness for heart disease and stroke.: https://www.goredforwomen.org/“Unfortunately, even in 2023, people still think the heart disease is a man's problem and don't really realize that it's also a women's problem; and that women have actually worse outcomes.” – Dr. Odayme Quesada Today's Health Bite: 80% of heart disease is preventable. 80%. It should actually be more about “What can we do so that we can beat this so that we don't have to worry about heart disease and men or women because it really is the number one killer for both?”Resources Mentioned:Cedars Sinai The Barbra Streisand Women's Heart Center at the Smidt Heart Institute: https://www.cedars-sinai.org/programs/heart/clinical/womens-heart.htmlDr. Bairey Merz: https://www.cedars-sinai.org/provider/cnoel-baireymerz-2285393.htmlWays to Connect with Dr. Odayme Quesada:LinkedIn: https://www.linkedin.com/in/odayme-quesada-2021605a/Instagram: https://www.instagram.com/odaymequesada/?hl=enWays to Connect with Dr. Adrienne Youdim:Email: dr@dradrienneyoudim.com Instagram: https://www.instagram.com/dradrienneyoudim/ Website: https://www.dradrienneyoudim.comRecommended Resource Hungry for More: Stories and Science to Inspire Weight Loss From the Inside Out by Dr. Adrienne Youdim If you love it and you think it is of benefit, please share this podcast with one person that you love. You can also go to http://www.dradrienneyoudim.com and sign up for my newsletter. If you prefer to get information in written form, you can get these tips via newsletter every week.

In this episode of CUBIST, Amanda and Don discuss the article, "Risk Factors for high symptom burden three months after traumatic brain injury and implications for clinical trial design: A TRACK-TBI study” by Nancy Temkin and colleagues, published in the Journal of Neurotrauma in June of 2022. Article Citation: Temkin, N., Machamer, J., Dikmen, S., Nelson, L. D., Barber, J., Hwang, P. H., Boase, K., Stein, M. B., Sun, X., Giacino, J., McCrea, M. A., Taylor, S. R., Jain, S., Manley, G., & TRACK-TBI Investigators (2022). Risk Factors for High Symptom Burden Three Months after Traumatic Brain Injury and Implications for Clinical Trial Design: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study. Journal of Neurotrauma, 39(21-22), 1524–1532. Article LINK: https://pubmed.ncbi.nlm.nih.gov/35754333/ CUBIST is a podcast for healthcare providers produced by the Traumatic Brain Injury Center of Excellence. We discuss the latest research on traumatic brain injury (TBI) most relevant to patient care. For more about TBI, including clinical tools, go to www.health.mil/TBICoE or email us at dha.TBICoEinfo@health.mil. The views, opinions, and/or findings in this podcast are those of the host and subject matter experts. They should not be construed as an official Department of Defense position, policy, or decision unless designated by other official documentation. Our theme song is “Upbeat-Corporate' by WhiteCat, available and was used according to the Creative Commons Attribution-Noncommercial 4.0 license.

Host: Monica Matthews CoHosts: Andrew Huff, TexasLindsay, TINDiscussion of SARS-N-COV2 Virus creation and the factors and individuals involved in the making of the virus that causes the COVID condition, how the vaccine has similar features and the associated risks in how the vaccine was developed and the choices made in doing so. Dr Adrew Huff's book, The Truth about Wuhan: How I Uncovered the Biggest Lie in HistorySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Host: Monica Matthews Co-Hosts: Dr. Andrew Huff, Christopher Moreno, TINSpecial Guests: Col John Hoffman, Charles RixeyDiscussion of How COVID was made and the coverup that occurred to hide from the public and the medical community what was done to create COVID the sars-n-cov19 Virus. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Richard Urso joins the show. Dr. Urso is a scientist, sole inventor of an FDA-approved wound healing drug, and the Former Director of Orbital Oncology at MD Anderson Cancer Center. Dr. Urso is also the Founder of Global Covid summit with 18K doctors around the world and he believes we cannot use a one-size-fits-all approach to fighting Covid. On today's show Dr. Urso and John discuss: Covid-19 vaccination and the associated risk factors The importance of early treatment and how it could have ended the pandemic The increase of cancer and latent disease Follow Dr. Richard Urso on Twitter. Listen to the Good Morning Liberty Podcast! Don't miss the “Dumb bleep of the week” every Friday where listeners vote on the dumbest thing said in politics that week. Get 15% off a God Hates Feds T-Shirt by using the promo code “LOL15”. Subscribe to John's Finding Freedom Show solo feed. Listen and Subscribe on Apple Podcasts and Spotify. Get access to all of our bonus audio content, livestreams, behind-the-scenes segments and more for as little as $5 per month by joining the Lions of Liberty Pride on Patreon OR support us on Locals! AND our new perk for $10 and up patrons 15% off coffee at Run Your Mouth Coffee! Check out our merchandise at the Lions of Liberty Store, including our hot-off-the-press t-shirt designs: TV is Filler for Pharma Ads and Making Myocarditis into Ourocarditis! Learn more about your ad choices. Visit megaphone.fm/adchoices

Host: Monica Matthews Co-Hosts: Dr Andrew Huff, TexasLindsay, TIN, Christopher MorenoDiscussion of the origins of MRNA research, viral vectors, gain of function and root of how COVID was made and what that means for the world. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Richard Urso joins the show. Dr. Urso is a scientist, sole inventor of an FDA-approved wound healing drug, and the Former Director of Orbital Oncology at MD Anderson Cancer Center. Dr. Urso is also the Founder of Global Covid summit with 18K doctors around the world and he believes we cannot use a one-size-fits-all approach to fighting Covid. On today's show Dr. Urso and John discuss: Covid-19 vaccination and the associated risk factors The importance of early treatment and how it could have ended the pandemic The increase of cancer and latent disease Follow Dr. Richard Urso on Twitter. Listen to the Good Morning Liberty Podcast! Don't miss the “Dumb bleep of the week” every Friday where listeners vote on the dumbest thing said in politics that week. Get 15% off a God Hates Feds T-Shirt by using the promo code “LOL15”. Subscribe to John's Finding Freedom Show solo feed. Listen and Subscribe on Apple Podcasts and Spotify. Get access to all of our bonus audio content, livestreams, behind-the-scenes segments and more for as little as $5 per month by joining the Lions of Liberty Pride on Patreon OR support us on Locals! AND our new perk for $10 and up patrons 15% off coffee at Run Your Mouth Coffee! Check out our merchandise at the Lions of Liberty Store, including our hot-off-the-press t-shirt designs: TV is Filler for Pharma Ads and Making Myocarditis into Ourocarditis! Learn more about your ad choices. Visit megaphone.fm/adchoices

Host: Monica Matthews, Co- Hosts: Tin, TexasLindsay, Christoper Moreno with special guest Charles Rixey expert in WMD mitigation and DRASTIC team In this episode we cover the Fauci Files and the thousands of documents Charles Rixey released to public as part of DRASTIC, additional discussions on gain of function research, and how covid was made and what made it so dangerous.From Twitter Spaces titled:Recap Space- RISK FACTOR- Why Covid Was Made (It Wasn't CHYNA)Breaking- Designer Bioagents delivered globally under Federal Programs See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

When A Heart Patient's Key Reasons For Recovery Included Nutritional Detoxification Baxter Montgomery, MD • https://montgomeryheart.com/ • Book - The Food Prescription for Better Health: A Cardiologists Proven Method to Reverse Heart Disease, Diabetes, Obesity, and Other Chronic Illnesses Naturally! #BaxterMontgomery#Cardiologist #PlantBasedDiet #WholeFood #Cholesterol Dr. Baxter D. Montgomery is an Author and Board-Certified Cardiologist with years of experience in the latest medical practices and nutritional health.  His Book, The Food Prescription for Better Health will help you find your prescription for optimal health in the foods you eat. For years Dr. Baxter Montgomery, has been helping patients overcome heart disease and other chronic illnesses through nutritional excellence. Now you can benefit from his knowledge and experience. The Book Features:• Outlines the poor health condition of Americans• Provides a detailed description of how the body works• Tells the real story of what healthy food is, dispelling many myths• Describes how proper nutrition is important for optimal health• Provides a step-by-step approach to reverse your health problems using nutrition• Shows scientific evidence for the efficacy of the program Dr. Montgomery is a Clinical Assistant Professor of Medicine in the Division of Cardiology at the University of Texas in Houston, a Fellow of the American College of Cardiology (FACC) and the founder and president of the Houston Cardiac Association (HCA).  Having seen many patients suffer the consequences of chronic heart disease, Dr. Montgomery founded the Montgomery Heart & Wellness Center in 2006 with the mission to reverse and prevent life-threatening illnesses. Located in Houston, Texas, The Montgomery Heart & Wellness Center is a state-of-the-art wellness facility complete with all the technology and resources to provide comprehensive medical and wellness care.  Combining his medical practice with a food-driven lifestyle intervention, Dr. Montgomery introduces patients to a novel food classification system that helps reverse chronic conditions such as heart disease, hypertension, obesity and diabetes without medications or surgeries.  He has refined this process over the past 10 years with profound positive results in severely ill patients. In addition to running Montgomery Heart & Wellness, Dr. Montgomery manages arrhythmias and coronary disease, performs angiographies, defibrillator implants and other hospital procedures, and teaches young physicians.  Dr. Montgomery earned his undergraduate degree from Rice University in Houston and his Medical Degree from The University of Texas Medical Branch in Galveston, Texas.  To Contact Dr. Baxter Montgomery Go to  MontgomeryHeart.com    Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Uterine cancer, also known as endometrial cancer, is the fourth most common cancer in women and the most common gynecologic cancer. 66,000  US women that are expected to be  diagnosed in 2023. Over the last fifteen years, while rates for colon, lung and other cancers have decreased, rates for uterine cancer have increased.  In this episode, Dr. Streicher covers: RISK FACTORS for uterine cancer Why women who have obesity are at increased risk  Why young women with PCOS are at increased risk Why perimenopausal women are at increased risk Why compounded hormone therapy and pellets increase risk Other risk factors that are not as well known Why Black women are twice as likely to die from uterine cancer Steps you can take to reduce your risk The #1 sign that you might have uterine cancer or pre-cancer What to know if you have been diagnosed with hyperplasia What to know if you have been diagnosed with uterine cancer For more information on this topic:       Episode 40 Don't Go with This Flow- Post Menopause Bleeding      Episode 11: Vaginal Estrogen is Not Poison      Episode 31 The TRUTH About Hormone Therapy: Does it CAUSE or Does it          PREVENT Breast Cancer?        Episode 52 Yes, You CAN Reduce Your Cancer Risk By 33% with Selene Yaeger Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Lauren Streicher, MD is a clinical professor of obstetrics and gynecology at Northwestern University's Feinberg School of Medicine, and the founding medical director of the Northwestern Medicine Center for Sexual Medicine and Menopause. She is a certified menopause practitioner of the North American Menopause Society.                   Sign up to receive DR. STREICHER'S FREE NEWSLETTER Dr. Streicher is the medical correspondent for Chicago's top-rated news program, the WGN Morning News, and has been seen on The Today Show, Good Morning America, The Oprah Winfrey Show, CNN, NPR, Dr. Radio, Nightline, Fox and Friends, The Steve Harvey Show, CBS This Morning, ABC News Now, NBCNightlyNews,20/20, and World News Tonight. She is an expert source for many magazines and serves on the medical advisory board of The Kinsey Institute, Self Magazine, and Prevention Magazine. She writes a regular column for The Ethel by AARP and Prevention Magazine.  Subscribe and Follow Dr. Streicher on  DrStreicher.com Instagram @DrStreich Twitter @DrStreicher Facebook  @DrStreicher YouTube  DrStreicherTV Books by Lauren Streicher, MD  Slip Sliding Away: Turning Back the Clock on Your Vagina-A gynecologist's guide to eliminating post-menopause dryness and pain Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Sex Rx- Hormones, Health, and Your Best Sex Ever The Essential Guide to Hysterectomy

On Episode 24 of the Stroke Alert Podcast, host Dr. Negar Asdaghi highlights two articles from the January 2023 issue of Stroke: “Covert Brain Infarction as a Risk Factor for Stroke Recurrence in Patients With Atrial Fibrillation” and “Subarachnoid Hemorrhage During Pregnancy and Puerperium.” She also interviews Dr. Georgios Tsivgoulis about his article “Clinical, Neuroimaging, and Genetic Markers in Cerebral Amyloid Angiopathy-Related Inflammation: A Systematic Review and Meta-Analysis.” Dr. Negar Asdaghi:         Let's start with some questions. 1) When during pregnancy is an intracranial aneurysm at the highest risk of rupture? 2) What does the presence of covert brain infarcts mean in the setting of atrial fibrillation? 3) And, finally, how is the inflammatory form of cerebral amyloid angiopathy different from the classic CAA form, and why is it important to differentiate between the two? We'll be answering these questions and much more in today's podcast. We're covering the latest in cerebrovascular disorders, and this is the best in Stroke. Stay with us. Welcome back to another issue of the Stroke Alert Podcast. My name is Negar Asdaghi. I'm an Associate Professor of Neurology at the University of Miami Miller School of Medicine and your host for the monthly Stroke Alert Podcast. Together with my co-editors, Drs. Nastajjia Krementz and Eric Goldstein, here's our article selection for the month of January. Symptomatic intracerebral hemorrhage is a feared complication of reperfusion therapies in acute stroke, so there's a lot of interest in looking for predictors of development of this complication, especially when you're making decisions for pursuing endovascular therapy. For many years now, we've known about some of these predictors, such as presence of a large infarct core and high blood glucose levels. But in the recent years, other radiographic markers of tissue viability, such as a poor collateral status and unfavorable venous outflow profile, have been shown to be predictors of post-reperfusion hemorrhagic transformation. In this issue of the journal, we learn about another imaging marker that can potentially predict parenchymal hemorrhage occurrence post-endovascular therapy, which is high hypoperfusion intensity ratio, or HIR, as measured by perfusion imaging. What is HIR? It's a long name for a simple ratio that can easily be measured by dividing the volume of tissue with Tmax delay of over 10 seconds to the volume of tissue with Tmax delays of over 6 seconds. Simply put, Tmax 10 divided by Tmax 6. These volumes, as you know, are typically provided to us by almost all post-processing perfusion softwares, and so this ratio can be easily calculated in the acute setting. So, in this paper led by Dr. Tobias Faizy from University Medical Center in Hamburg and colleagues, we learned that higher hypoperfusion intensity ratios are strongly associated with parenchymal hemorrhage occurrence after endovascular therapy. So, in summary, HIR, that is a quantitative ratio, can be used as a marker to risk stratify patients that are undergoing endovascular therapy in terms of helping us predicting the risk of development of intracerebral hemorrhage after reperfusion therapies. In a separate study in this issue of the journal, we read a very interesting paper titled "Anti-Epileptic Drug Target Perturbation and Intracranial Aneurysm Risk." How are intracranial aneurysms even related to anti-epileptic drugs? Well, first of all, it's been known for a long time based on genome-wide association studies that there are multiple common genes that are associated with increased risk of intracranial aneurysm development. Now, some of the largest genetic studies to date have shown pleiotropy between genetic causes of development of intracranial aneurysms and genes encoding targets for anti-epileptic drugs. Now that's a fascinating finding because finding commonalities between these genes may help find new treatment targets for intracranial aneurysms. So, in this paper in this issue of the journal, the investigators from the University Medical Center in Utrecht found an association in the expression of anti-epileptic drug target gene CNNM2 and intracranial aneurysm risk. They found that certain anti-epileptic drugs, such as phenytoin, valproic acid, and carbamazepine, that are expected to lower CNNM2 levels in the blood may subsequently lead to a lower risk of development of intracranial aneurysms. And, of course, a reasonable follow-up study to this would be to investigate whether persons exposed to these anti-epileptic drugs have indeed a lower risk of unruptured intracranial aneurysms and subarachnoid hemorrhage, and how variation in CNNM2 expression can lead to development of aneurysms. Bottom line, CNNM2 may be a relevant drug target for treatment of cerebral aneurysms. As always, I encourage you to review these papers in detail in addition to listening to our podcast today. My guest on the podcast today is the Chairman of Neurology at the University of Athens, Dr. Georgios Tsivgoulis. He joins me all the way from Greece to talk about cerebral amyloid angiopathy-related inflammation, or CAA-ri. He's a remarkable researcher, and I can say with absolute confidence that we cannot find a better summary of this very tough topic elsewhere. He ends the interview with an intriguing account of the early description of dementia in Greek mythology. But first, with these two articles. What are covert brain infarcts, or CBIs? Are these the John Wick or the James Bond of the stroke world? After all, they operate undercover. They're ominous and attack without warning. That's probably why they're also called silent infarcts. Now, whatever we call them, we need to know how prevalent they are and what does their presence actually mean. Let's dive into this topic. For at least two centuries, if not longer, we've known about covert brain infarcts. Early description of these lesions is credited to Amédée Dechambre, a medical intern at Salpêtrière Hospital in Paris who noted that there are strokes that can cause symptoms like hemiplegia, but also strokes that are asymptomatic, or so he thought at the time. In the modern times, while we agree with our pathology forefathers that CBIs are different from symptomatic strokes, we also know that they are not entirely asymptomatic. The symptoms can be subtle and tend to sneak up on the patient, but what is clear is that amassing of covert brain infarcts results in an overall decline in cerebrovascular reserve of the brain. With the advent of neuroimaging, we now know that CBIs are age-dependent and prevalent, seen in almost 10 to 30% of even healthy adults, but much more prevalent in those with vascular risk factors, and they can be caused by nearly the entire spectrum of neurovascular disease, including large vessel, small vessel disorders, cardioembolism, and others. Now, how do these covert infarcts catch up in those with atrial fibrillation? Neuroimaging studies have shown that patients with A-fib, especially those untreated, have a higher percentage of embolic-appearing CBIs, and conversely, those with embolic formed pattern of CBIs are more likely to have undiagnosed A-fib. So the question is, what's the significance of CBI in those with confirmed A-fib? In this issue of the journal, Dr. Do Yeon Kim from Seoul National University and colleagues help us answer this question using the EAST-AF, which stands for East Asian Ischemic Stroke Patients With Atrial Fibrillation Study. So, the paper included over 1300 patients with A-fib and first-ever stroke without a prior history of TIA or stroke. And then they categorized these patients into those who had evidence of CBI on neuroimaging and those who didn't. So, what did they find? Forty-two percent of patients with A-fib and first-ever stroke had evidence of covert brain infarcts on neuroimaging. Let's think about it for a moment. These patients presented with what was thought to be their first-ever stroke, not knowing they already had some in their brain. Now, what makes things really worse is that over a quarter of these subjects had more than just one covert infarct. Not surprisingly, those with CBI tended to be older, had higher blood pressure, and had worse white matter hyperintensity burden. This is kind of expected and also not expected was the fact that most of these covert infarcts were actually embolic in pattern. Over 60% of them were embolic. Another 14% of cases had combined embolic and non-embolic-appearing CBIs. Now, overall, the one-year incidence of ischemic stroke and all-cause mortality was higher in those that had CBIs at baseline. When they started looking at the specific patterns of CBIs, those embolic-appearing CBIs had a threefold higher risk of recurrent ischemic stroke, whereas those with non-embolic-appearing covert infarcts had oddly a higher all-cause mortality rate but not recurrent ischemic stroke. And finally, just briefly, the authors noted that the addition of CBIs to the classic CHA2DS2-VASc score didn't meaningfully otherwise statistically improve the scoring metrics, so they left it at that. So, the take-home message is that 42% of A-fib patients presenting with first-ever stroke actually had prior strokes without even knowing based on this study. And most of these strokes were embolic-appearing, and these covert brain infarcts can be used as predictors of future clinical strokes in this population. Strokes should be the last thing to worry about when we think of pregnancy. In the United States, around 30 in 100,000 women, unfortunately, experienced a stroke during pregnancy, and between 6 to 8 in 100,000 deliveries are complicated by subarachnoid hemorrhage. What's the most common cause of pregnancy-associated subarachnoid hemorrhage? In the general population, close to 80% of subarachnoid hemorrhage cases are aneurysmal. Is this true for the pregnant population as well? And importantly, what's the contemporary incidence trend, risk factors, and outcomes of pregnancy-related subarachnoid hemorrhage? In this issue of the journal, Dr. Korhonen and Petra [Ijäs] and their colleagues from the Departments of Neurology and Obstetrics and Gynecology at Helsinki University Hospital will give us the answers to some of these questions through a nationwide population-based study in Finland. So, they looked at over one and a half million pregnant women who gave birth during a 30-year time period between 1987 to 2016. Subarachnoid hemorrhage was identified through appropriate ICD codes and then further adjudicated based on confirmatory information, including neuroimaging and data from lumbar puncture. A total of 57 cases of pregnancy-related subarachnoid hemorrhage was identified in this paper. The mean age of women was 33, ranging from 23 to 45, and the clinical presentation was typical for subarachnoid hemorrhage, including thunderclap headache and mild neurological symptoms. So, what did they find? So, first off, in terms of general observations, the overall incidence rate of pregnancy-related subarachnoid hemorrhage in this study was 3 over 100,000 deliveries. This is almost half the incidence rate reported from the nationwide registries in the United States. Seventy-seven percent of pregnancy-related subarachnoid hemorrhage cases were aneurysmal, so very similar to the general population. The other 23% were non-aneurysmal cases, but it's important to note that 40% of those non-aneurysmal cases also had vascular etiologies, so etiologies such as moyamoya syndrome, postpartum angiopathy, AVM, to name a few. Like non-pregnant patients with subarachnoid hemorrhage, the aneurysmal cases were sicker patients in general. They had a lower GCS at presentation, higher Hunt and Hess scores, and required more ICU admissions. The next finding is very important because it actually shows that development of subarachnoid hemorrhage during pregnancy significantly impacted obstetrical care. A total of 66% of women with subarachnoid hemorrhage during pregnancy ended up having a C-section and a high percentage of these cesarean sections were actually elective. This is in contrast with subarachnoid hemorrhages in the postpartum period where 67% of women had spontaneous vaginal deliveries. The other important finding of the paper was really highlighting the differences between pregnancy-related aneurysmal versus non-aneurysmal subarachnoid hemorrhages. We already talked about how, in general, aneurysmal cases had more severe neurological presentations, so, not surprisingly, they also had worse outcomes with a mortality rate of 16% for the aneurysmal subarachnoid hemorrhage cases, and only 68% of women with pregnancy-related aneurysmal subarachnoid hemorrhage reached a favorable outcome, which was defined in this study as modified Rankin Scale of 0 to 2. Other important differences included the fact that the incidence of aneurysmal subarachnoid hemorrhage increased towards the end of pregnancy and was highest in the third trimester. This ties in with the findings from prior studies all indicating that rupture of an aneurysm is most common in the third trimester. By contrast, the incidence of non-aneurysmal subarachnoid hemorrhage peaked in the second trimester in this study. And finally, in terms of risk factors, first let's talk about age. The incidence rate of pregnancy-associated subarachnoid hemorrhage increased with age of the mother. So, in this study, there were no cases noted amongst women aged below 20 years of age to an incident rate of 12 per 100,000 deliveries among women aged 40 years or over. So that's a fourfold increase from the overall incidence rate of pregnancy-related subarachnoid hemorrhage, and very important point that we learned from this paper. Apart from age, smoking beyond 12 weeks of gestation and hypertension were also independent factors associated with pregnancy-related subarachnoid hemorrhage. So, overall, hypertension, smoking are bad and are significant risk factors for pregnancy-related subarachnoid hemorrhage. And if we have to remember just one thing from this paper, let it be this one: The rupture of an aneurysm is most common in the third trimester of pregnancy. Cerebral amyloid angiopathy, or CAA, is an important cause of intracranial hemorrhage and refers to deposition of β-amyloid fibrils in the wall of the small- and medium-sized cerebral blood vessels, mostly involving cortical and leptomeningeal arteries. It is believed that the deposition of β-amyloid results in architectural disruption of the blood vessels, which then leads to perivascular leakage. That's the pathophysiological mechanism behind the development of cerebral microbleeds. And this process, of course, can cause frank vascular rupture resulting in cortical intracerebral hemorrhage or development of high-convexity subarachnoid hemorrhages. It is important to note that varying amounts of perivascular inflammation, that is inflammation surrounding β-amyloid-laden blood vessels, may be present in some CAA cases, rendering them the designation of inflammation-related CAA. However, frank vasculitic destruction of the vessel wall, such as what is found in amyloid-β-related angiitis, or ABRA, and primary angiitis of the central nervous system, is usually absent in most CAA-related inflammation cases. How these entities are best defined, diagnosed, and treated is subject of intense research. In this issue of the journal, in the study titled "Clinical, Neuroimaging, and Genetic Markers in CAA-Related Inflammation," Dr. Georgios Tsivgoulis and colleagues take us through a systematic review and meta-analysis of published studies of patients with CAA-related inflammation. I am joined today by Dr. Tsivgoulis himself to discuss this paper. He's a Professor of Neurology and Chairman of the Second Department of Neurology at the University of Athens School of Medicine. Dr. Tsivgoulis is the residency program director and the director of cerebrovascular fellowship program with extensive research and expertise in the field of stroke. Good morning, Georgios, and welcome to our podcast. Dr. Georgios Tsivgoulis: Good morning, Negar. I'm delighted to be here and delighted to present our findings, on behalf of all our co-authors. Dr. Negar Asdaghi:         Thank you very much for being here and congrats again on the paper. So, Georgios, let's start with this interest that's going on with using clinical and radiographic features to make the diagnosis of CAA-related inflammation in contrast to moving ahead and performing brain biopsy. Can you please start us off with a brief review of the newly proposed clinico-radiographic criteria for this condition, please? Dr. Georgios Tsivgoulis: Yes. As you mentioned, Negar, CAA-ri is a distinct, however, rare subset of cerebral amyloid angiopathy. Firstly, Greenberg and the Boston group published in Neurology in 2007 a paper highlighting that a diagnosis of a probable CAA-ri patient could be made on the basis of characteristic clinical and neuroimaging findings without requiring a biopsy. Following this observation, Chung and colleagues in 2010, in a seminal paper in JNNP, proposed the first diagnostic criteria for probable and definite CAA-ri. For the definite diagnosis, besides the typical clinical presentation with headache, encephalopathy, focal neurological signs and seizures, and the characteristic neuroimaging findings with T2 or FLAIR hyperintense asymmetric white matter lesions complicated with microbleeds and leptomeningeal or parenchymal gadolinium enhancement, and histopathological confirmation with amyloid deposition within cortical leptomeningeal vessels associated with perivascular, transmural or intramural inflammation was also required. The latest criteria developed in 2015 by Auriel and colleagues that were published in JAMA Neurology using a validation study modified the current criteria for the diagnosis of CAA-ri. In this paper, the author supported the use of empirical immunosuppressive therapy, avoiding brain biopsy, for patients meeting the criteria proposed for probable CAA-ri. They suggested that a brain biopsy should be considered in empirically treated patients who failed to respond to corticosteroid therapy within three weeks. The criteria by Auriel and colleagues are widely applicable in everyday clinical practice, and we also use this criteria for the inclusion of studies in our current meta-analysis. I would like to highlight for our audience that the latest criteria for CAA-ri were published in 2015 by Auriel and colleagues. However, these are different for the criteria for cerebral amyloid angiopathy than the latest criteria were published in 2022 in Lancet Neurology, OK? Dr. Negar Asdaghi:         Georgios, that was a great start for this interview. You had mentioned a lot of information here. I just want to highlight what you just said. So, we are using for this meta-analysis, the latest criteria in CAA-related inflammation published in JAMA by Auriel and colleagues. That's slightly different than, we're not referring to the 2022 criteria of cerebral amyloid angiopathy. It's an important distinction. We're going to talk about this a little more as we go through the interview, but I want to come back to your current paper and start from there. Can you please tell us about the importance of this paper, why doing a meta-analysis was important in your view, and tell us a little bit about the studies that were included in your paper? Dr. Georgios Tsivgoulis: Yes, thank you for that question. CAA-ri is an increasingly recognized entity since the recent diagnostic criteria by Auriel and colleagues published in 2015. In collaboration with the greater availability of the high-resolution MR, we can have now a reliable non-invasive diagnosis of possible or probable CAA-ri, avoiding the risk of brain biopsy. However, I need to highlight that the early diagnosis remains a great challenge for the clinicians and neurologists. Searching the literature, we observe that there is scarce data regarding the prevalence of the distinct clinical, neuroimaging, and genetic markers among patients diagnosed with CAA-ri. We believe that pooling all this information in the current meta-analysis would be very helpful for every clinician, increasing a comprehensive understanding of this rare cerebrovascular disorder. Consequently, we conducted this meta-analysis including 21 studies that recruited a total of 378 patients with CAA-ri. Our study involved only 4 prospective and 17 retrospective hospital-based cohorts of patients diagnosed with CAA-ri based on autopsy or biopsy or on the recent Auriel diagnostic criteria that do not require autopsy or biopsy. Due to limited data in the literature regarding this entity, we had to include only small cohort studies with at least five patients in our meta-analysis. We excluded case reports and case series with less than five patients. This is, by far, the largest available sample of CAA-ri patients in the literature. Dr. Negar Asdaghi:         OK, great. So, let me just recap this, more so for myself. So, we have 21 studies, and you excluded studies that included less than 5 patients. So, practically speaking, case reports. Dr. Georgios Tsivgoulis: Yes, and single-case reports. Dr. Negar Asdaghi:         Yes. And practically speaking, of the total number of patients that are included in this meta-analysis, you have 378 cases, and basically the diagnosis of CAA-related inflammation was either based on the newly proposed criteria or based on biopsy-confirmed or autopsy cases. Dr. Georgios Tsivgoulis: Which is the standard criteria. Dr. Negar Asdaghi:         So, now, I'm dying to ask you about these clinical and radiographic characteristics of patients with CAA-related inflammation in this meta-analysis. Dr. Georgios Tsivgoulis: The mean age of patients in the included studies was approximately 72 years old, and there was no obvious gender predominance. Fifty-two percent of the patients were of female sex. In our study, 70% of the included patients presented with cognitive decline, which was the most common neurological manifestation, while 50% of the total sample had focal neurological signs and 54% encephalopathy presentation. Symptoms such as headache and seizures were less common, 37 and 31% respectively. With regard to the radiological findings, hyperintense T2 FLAIR white matter lesions were very, very common in 98% of our patients, and they were also complicated with lobar cerebral microbleeds, with a prevalence of 96%, and these two were, by far, the most prevalent neuroimaging findings, that white matter hyperintensities coupled with a cerebral microbleed. The pooled prevalence rates of gadolinium-enhanced lesions was 54%, and also the prevalence of cortical superficial siderosis was 51%, which is also very high in this cohort of patients with CAA-ri. Dr. Negar Asdaghi:         OK. So many of the features Georgios said, you mentioned, from presence of white matter hyperintense lesions on T2 FLAIR to presence of cortical microbleeds or superficial siderosis, these features are also seen in patients with cerebral amyloid angiopathy. What are some of the important differentiating features between the two conditions? Dr. Georgios Tsivgoulis: Yes, this is an excellent clinical question. First of all, the lower age threshold for CAA-ri is 40 years old, whereas in cerebral amyloid angiopathy, the lower age threshold is 50 years. So, patients who are younger than 50 years can be diagnosed with CAA-ri, but they cannot be diagnosed with CAA. Another issue is that comparing the result of this meta-analysis with another recent meta-analysis focusing on CAA, on cerebral amyloid angiopathy, that our international multi-collaborative group published in Stroke in 2002, we also evaluated the presence of clinical phenotypes and radiological markers among patients with cerebral amyloid angiopathy. We have documented that transient focal neurological episodes are much more common in patients with cerebral amyloid angiopathy in contrast to patients with CAA-ri. These episodes, which are called TFNEs, transient focal neurological episodes, are attributed to cortical subarachnoid hemorrhage or cortical superficial siderosis. So, I think this is another important clinical distinction. The most important, however, differentiating features between the two entities are neuroimaging markers, in specific, in particular, T2 FLAIR hyperintense unifocal or multifocal lesions with mass effect. These are the most prevalent neuroimaging features among patients with CAA-ri, but they're very seldomly described in patients with cerebral amyloid angiopathy, in patients with CAA. Another characteristic neuroimaging finding very indicative of the inflammation is the leptomeningeal or parenchymal gadolinium enhancement. This finding has been very rarely described in patients with non-inflammatory cerebral amyloid angiopathy. So, the clinical distinction is not so solid. However, the neuroimaging distinction would provide us with very strong information that can help us differentiate these two conditions. Dr. Negar Asdaghi:         Excellent points, I have to say, golden points, not just excellent points. I'm going to try to recap this and see if I understood it correctly. So, for our listeners, we have two conditions that potentially have many common points. One is the cerebral amyloid angiopathy, and the second one, which is obviously the subject of this interview, is cerebral amyloid angiopathy-related inflammation. The most important differentiating factors between the two are actually the neuroimaging features, as Georgios mentioned. So, the first feature that was mentioned is presence of T2 FLAIR hyperintense lesions. Some of them are large and have actually mass effects. This feature is rarely seen in patients with CAA, and it's an important radiographic factor that is seen in patients with CAA-related inflammation. The second distinguishing feature was leptomeningeal enhancement, again, rarely seen in non-inflammatory CAA, but was seen in a significant proportion of patients with CAA-related inflammation. These were the neuroimaging features. You also mentioned two other factors. The median age of CAA-related inflammation was lower than CAA. That can be helpful. And also the entity of transient focal neurological episodes, or TFNE, is rarely seen in inflammatory cases of CAA, whereas it is described in cases with cerebral amyloid angiopathy and mostly related to development of either cortical subarachnoid hemorrhage or cortical superficial siderosis. I think I got this all, correct? Dr. Georgios Tsivgoulis: Excellent. Dr. Negar Asdaghi:         All right, so let's come now to the genetics of CAA. The apolipoprotein E gene is associated with the presence of amyloid angiopathy and development of lobar intracerebral hemorrhage, and we've learned about this in cases with cerebral amyloid angiopathy. Is there an association with ApoE, and did you find anything in this meta-analysis? Dr. Georgios Tsivgoulis: Another very exciting question. In 2007, there was a first report that the apolipoprotein ε4 homozygosity may be considered a risk factor for CAA-ri, and there was a strong correlation reporting a high prevalence of 77% of this apolipoprotein ε4 alleles among patients with CAA-ri. To justify this correlation, the hypothesis was that an underlying pathogenic mechanism, which increases the amyloid-β deposition and has a pro-inflammatory effect, may be suspected as the cause of this disorder. The largest, however, prospective cohort of CAA-ri patients conducted by Antolini and colleagues and was published in 2021 in Neurology, reported a much lower prevalence of apolipoprotein ε4 carriers accounting for 37%, 23% heterozygotes and 14% homozygotes. So, we also documented a pool prevalence of apolipoprotein ε4 homozygosity of 34%. So, we did not confirm the initial finding of 77%. However, in our meta-analysis, the homozygosity was 34%, and we need to have a cautious interpretation of these results because data is limited, and we need larger future population-based studies and in larger cohorts to evaluate the prevalence rate of these specific genetic markers. So, we can confirm an association between apolipoprotein ε4 homozygosity, however not as strong as originally reported in 2007. Dr. Negar Asdaghi:         OK. So, Georgios, thank you. And again, very important factor to keep in mind for our clinicians listening in. Unfortunately, based on what you mentioned, we don't have yet a genetic marker to, for sure, tell us if we're dealing with CAA-related inflammation, yes or no, as you mentioned. Just to recap, earlier on, there was studies to suggest a very strong association between apolipoprotein ε4 homozygosity and CAA-related inflammation. But later on, this was not confirmed by subsequent studies, and in your meta-analysis, you found 34% ApoE ε4 homozygosity amongst patients with CAA-related inflammation and could not confirm that original high association. OK, so with all of that, it's a lot of information. I have to go to the next question regarding controversies involving the levels of Aβ40, Aβ42, and P-tau proteins in CSF in the setting of CAA-related inflammation. Can you please tell us more about these biomarkers? Dr. Georgios Tsivgoulis: Yes. The overlap of Alzheimer's disease and CAA can be attributed to the coexistence of some degree of cerebrovascular amyloid deposition and amyloid plaque pathology, which is very common. And, of course, the evaluation of amyloid and tau proteins in CSF is of high significance for the prognosis and the evolution of CAA patients. In our previous review, we have summarized the literature and noticed that CSF concentrations of Aβ40 and, secondarily, Aβ42 were much lower in patients with cerebral amyloid angiopathy compared with Alzheimer's disease. Total tau and phospho-tau CSF levels were comparable to healthy controls in CAA and lower than patients with Alzheimer's disease. Moving now to CAA-ri, there were scarce data about these biomarkers amongst CAA-ri patients. The majority of the relevant studies have found relatively low levels of Aβ42 and Aβ40 in the CSF and high levels of P-tau. In the present meta-analysis, the pooled means of biomarker levels were based on the findings of only two studies with heterogeneity, and these limit substantially the validity of our observations. However, they confirm the previous reports indicating, as I said before, but I would like to repeat, low levels of Aβ42 and Aβ40 in the CSF and high levels of P-tau. Dr. Negar Asdaghi:         Perfect. So, thank you, Georgios. I'm going to recap what you said. So, we're talking about CSF biomarkers, and first what you mentioned is going back to the original studies concentrated on using these biomarkers as ways of differentiating between cerebral amyloid angiopathy and Alzheimer's disease. And very briefly, to recap what you said, in general, the levels of Aβ40 and, secondarily, Aβ42 was found to be much lower than the Alzheimer's levels in patients with CAA. Now coming to the inflammatory form of CAA, what you mentioned and what you found in this meta-analysis, practically speaking, confirmed that the levels of Aβ40 and Aβ42 in CSF are low and the levels of P-tau are high in this condition as well. So, one thing I want to ask as a secondary question to that is, that it sounds like these biomarkers are more or less similar in CAA and CAA -related inflammation, not that different. Is that correct? Dr. Georgios Tsivgoulis: It's absolutely correct. And I would also like to highlight a major limitation of the meta-analysis that we had available data from only two studies to pool the mean of these CSF biomarker levels. So, these results need to be acknowledged with caution, and we would love to repeat our meta-analysis after the publication of more studies and prospective cohorts measuring the CSF biomarkers in patients with CAA-ri. Dr. Negar Asdaghi:         OK. So, again, important to note, as you mentioned, that there's heterogeneity in data because of just paucity of information on this, but as we stand today, the biomarkers won't really help us in terms of differentiating between the two conditions that are CAA or CAA-related inflammation. And so, I think I've learned a lot from this interview myself, but I think we have to just talk briefly about the available therapies for CAA-related inflammation. Dr. Georgios Tsivgoulis: Yes. In our meta-analysis, we sought to summarize the available information regarding different therapeutic strategies and outcomes among CAA-ri patients. Our results supported our clinical experience indicating that corticosteroids represent the first-line treatment in these patients' outlook. Steroids have been associated with clinical and radiological improvement of the primary disease episode and decreased risk of subsequent relapses in patients with CAA-ri. Additional immunosuppressive therapies, including cyclophosphamide, mycophenolate mofetil, azathioprine, IVIG, or rituximab, have been also reported as adjunct therapies in selected cases with a more severe course of the disease. However, this is another limitation that needs to be acknowledged. That data regarding the treatment and the outcomes are limited and heterogeneous, which prevented us from drawing robust conclusions using a meta-analytical approach. And we believe that we need future cohort studies with prospective data validation in order to generate a proposal for a therapeutic algorithm management in these cases. Dr. Negar Asdaghi:         Thank you, Georgios. So, we have a condition that is now being more and more recognized. We now have criteria based on clinical and radiographic presentation features of patients that might help us with this diagnosis to differentiate it from cerebral amyloid angiopathy. And in terms of therapies, the idea is that the most studied drug is really just first-line therapy, that's corticosteroids. And then there's positive data regarding use of all other forms of immunosuppression, including, as you mentioned, cyclophosphamide, rituximab, and oral agents such as mycophenolate mofetil or azathioprine. We have limited information about those, but I want to highlight something you actually mentioned earlier on in the interview, which is the field is moving towards making these diagnoses based on clinical features and radiographic features that you had highlighted and actually giving patients immunosuppression early on and only move on to a biopsy if the patient had failed these therapies for a period of time, which you mentioned three weeks. So, I think it's important for us as clinicians to keep this evolving criterion and recommendations in mind. And before we end, I want to ask you a hypothetical question, Georgios. In your opinion, what's an ideal randomized trial for CAA-related inflammation in the future? Dr. Georgios Tsivgoulis: I think before going to the randomized, the ideal randomized trial for CAA-ri, and designing this trial, we need much more information regarding the underlying pathophysiological mechanisms. There are many unanswered questions. What is the diagnostic value of CSF biomarkers such as amyloid, we discussed earlier, and tau protein? And, of course, what is the value of CSF and the amyloid-β autoantibodies, if there is any? What is the value of genetic markers such as apolipoprotein E genotype and a correlation with the co-existing inflammation in CAA-ri? However, I don't want to defer this question. So, a typical answer would be that with regard to the ideal patients, we would want a young patient without comorbidities after the first manifestation of CAA-ri who has shown a good clinical and radiological response to corticosteroids in order to define the best second-line therapy. However, before answering all these questions in a clinical trial, if we can, I think that we need to understand the CSF and genetic biomarkers in order to uncover mechanisms regarding pathophysiology that can help us to design more targeted clinical trials studying novel disease-modifying treatments. Dr. Negar Asdaghi:         Thank you. Dr. Georgios, it's been a pleasure having you on the podcast, and I can say we've learned a lot. We look forward to having you back here and talk about that hypothetical randomized trial, and I'm sure one day hopefully will happen in our lifetime. Thank you for being here. Dr. Georgios Tsivgoulis: Thank you. Thank you for having me. It was a pleasure. Dr. Negar Asdaghi:         Thank you. Homer, the legendary Greek poet, described a case of dementia in his seminal work, The Odyssey, in the late eighth century before Christ. He described the cognitive decline of Odysseus's father, King Laertes. The detailed account of the king's mental decline, loss of short-term memory with retention of long-term memory combined with his depression and despair over the loss of his son, is dramatically accurate for a nearly 3,000-year-old description of dementia. Before I ended the interview, I had to use this opportunity to ask Georgios about lessons learned from ancient Greeks and this seemingly timeless disease. Dr. Georgios Tsivgoulis: Thank you for this question. King Laertes was indeed Odysseus's father, and it's a great paradigm describing dementia. However, the ancient history of dementia may be separated according to the Greek philosopher Posidonius in two periods. The first period is called dementia appearing due to old age, which is called in Greek, eros. And the second one is dementia appearing in other ages and mainly due to other reasons, called morosis. Posidonius of Rhodes was a Greek stoic philosopher of the second first century BC who strongly believed and suggested that morosis, which is that dementia appearing in younger ages due to other disorders, should be treated immediately after its onset. So, if I would like to end this podcast, I would just suggest that CAA-ri could be classified as morosis according to Posidonius. And what we could learn is that the early diagnosis is essential since the prompt initiation of corticosteroids should not be unreasonably delayed. Dr. Negar Asdaghi:         And this concludes our podcast for the January 2023 issue of Stroke. Please be sure to check this month's table of contents for the full list of publications, including a series of Focused Updates on post-stroke neurological recovery, from management of post-stroke attention deficit, neglect and apraxia to post-stroke memory decline. And with this, we end the start of our 2023 podcast series. Like all new things, a new beginning can come with new directions, and sometimes a new direction is all that we need. After all, as the legend has it, it was a direction of that falling apple back in the year 1666 that gave Isaac Newton the idea of the universal law of gravitation. Now, Isaac Newton has, without a doubt, given science some of its biggest discoveries in mathematics, physics, and astronomy. But most may not know that Newton had a pretty rough start in life. A January-born premature baby, he was thought not to survive the first few days of life. Newton had a difficult childhood, and at the age of 16, he was pulled out of school by his family and forced to become a farmer, a job he didn't like and he was miserably bad at. So, as we start a new year, let's remember that even the smartest people are not good at everything, and it does take time to find one's passion in life. Now, while things may not always be clear, what is clear is that a great way to find that center of gravity is, as always, staying alert with Stroke Alert. This podcast is produced by Wolters Kluwer and supported by the editorial team of Stroke. Our Stroke Alert podcast and production staff includes Danielle Cross, Eric Goldstein, Nastajjia Krementz, Ishara Ratnayaka, Erinn Cain, Rebecca Seastrong, and Negar Asdaghi. This program is copyright of the American Heart Association, 2023. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit AHAjournals.org.

What is bio surveillance? Is there a correlation between Covid19 and global pandemics? A matter of national security or nefarious intent? The answers may surprise youSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Elyn takes you through 13 papers from October 2022 published on vascular contributions to Alzheimer disease. It's quite the journey through mechanistic mouse studies, neuroimaging studies, and a few studies assessing treatments targeting the vasculature, which all paint a pretty convincing picture of the importance of the cerebrovasculature in brain health. Tune in to learn more about the glymphatic system, consequences of amyloid deposition on the vasculature, and a clinical study testing out albumin replacement as an AD treatment!   Sections in this episode:  Vascular Implications of Amyloid Accumulation (3:52) Glymphatic System (7:31) Other Clinical Studies (10:57) Co-morbidities and Risk Factors (15:20) Treatment Avenues (22:15) -------------------------------------------------------------- To find the numbered bibliography with all the papers covered in this episode, click here, or use the link below:https://drive.google.com/file/d/1I1UBwfShuf9D9GH9mkGZJd2HkQzNt65v/view?usp=share_linkTo access the folder with ALL our bibliographies, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharingYou can also find all of our bibliographies on our website: amindr.com. --------------------------------------------------------------Follow-up on social media for more updates!Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastFacebook:  AMiNDR  Youtube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com  -------------------------------------------------------------- Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don't forget to subscribe to hear about new episodes as they come out too. Thank you to our sponsor, the Canadian Consortium of Neurodegeneration in Aging, or CCNA, for their financial support of this podcast. This helps us to stay on the air and bring you high quality episodes. You can find out more about the CCNA on their website: https://ccna-ccnv.ca/. Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was scripted and hosted by Elyn Rowe, edited by Scott Prins, and reviewed by Cassi Friday and Anusha Kamesh. The bibliography and wordcloud were created by Lara Onbasi (www.wordart.com). Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For October 2022, the sorters were Sarah Louadi, Eden Dubchak, Ben Cornish, Christy Yu, Dana Clausen, Kevin Nishimura, Salodin Al-Achkar, and Elyn Rowe. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Lara Onbasi, Joseph Liang, and Judy Cheng, for keeping everything running smoothly.Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  --------------------------------------------------------------*About AMiNDR: *  Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

Host Dr. Conor Kleweno interviews paper authors Dr. Dane Brodke and Dr. Christopher Lee as they discuss this multi-center retrospective review rom 10 centers. This paper was presented at the 2022 OTA Annual Meeting. For additional educational resources visit https://ota.org/ To see the abstract while you listen, as well as explore OTA CME podcast episodes, download the ConveyMED App for free: Apple Store click here  Google Play click here

Dr. Andrew Huff, Author, former VP of Ecohealth Alliance and I team up for a Twitter Space series regarding all things COVID Genesis. "Covid was designed to do what it did" Special Guests, Col John Hoffman US Army (RET) along with Charles Rixey- USMC WMD Expert and Consultant Texas Lindsay join me to put the pieces no one wants to expose. How do they know? They were there.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this “Ask Me Anything” (AMA) episode, Peter answers questions related to the leading cause of death in both men and women—atherosclerotic cardiovascular disease (ASCVD). He highlights the most important risk factors for ASCVD, such as apoB, LDL, hyperinsulinemia, and Lp(a), and explains the mechanism by which they confer risk and how these factors are interrelated. Peter also dives deep into the data around apoB to try to answer the question of how much residual risk is conferred for ASCVD through metabolic dysfunction once you correct for apoB. He also looks at the data around lifetime risk reduction of ASCVD in the context of low apoB. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #42 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: A racecar analogy for understanding atherosclerotic cardiovascular disease [2:00]; Defining and differentiating apoB and LDL-C [10:00]; The interrelated nature of insulin levels, apoB, triglycerides, and ASCVD parameters [13:00]; Another way that hyperinsulinemia plays a role in endothelial dysfunction [18:00]; Why Peter uses the oral glucose tolerance test (OGTT) with all patients [20:15]; Is there any evidence that hyperinsulinemia is an independent contributor to ASCVD? [23:00]; Thinking through risk in the context of high-fat diets resulting in improved metabolic metrics but with an elevation of apoB/LDL-C [27:30]; Thinking through risk in the context of low apoB but higher than normal triglyceride levels [32:15]; The importance of lowering apoB for reducing ASCVD risk [38:15]; Data on men and women with familial hypercholesterolemia that demonstrates the direct impact of high apoB and LDL-C on ASCVD risk [47:45]; Importance of starting prevention early, calcium scores, and explaining causality [52:30]; Defining Lp(a), its impact on ASCVD risk, and what you should know if you have high Lp(a) [56:30]; Lp(a) and ethnic differences in risk [1:00:30]; Why someone with elevated Lp(a) should consider being more aggressive with apoB lowering strategies [1:05:00]; Addressing the common feeling of hesitancy to taking a pharmacologic approach to lower ASCVD risk [1:07:15]; Peter's take on the 2022 Formula 1 season and thoughts on 2023 [1:15:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

What do I need to know about strokes?Strokes are largely preventable, and knowing the signs is critical.Strokes are the number five cause of death and a leading cause of disability in the United States. They occur for 2 reasons: a clot or obstruction of blood flow to the brain (called “Ischemic") and when a blood vessel ruptures ("hemorrhagic"). Both cause death in regions of the brain from lack of oxygen and blood flow. Regardless of type, the likelihood is you either know someone or will know someone who suffers a stroke. Fortunately, the American Stroke Association says 80% of strokes are preventable.Senior Services Expert Lori Williams dives into the factors we can control, such as lifestyle, to prevent a stroke. She also shares the signs someone is having a stroke so you can quickly recognize them in your loved one. Noticing these signs are vital – as Lori can attest. This week, she gets personal and shares her own experience over Christmas when her husband Mark, suffered a stroke. You can remember the signs of a stroke with the acronym F.A.S.T.:- F: Face drooping- A: Arm weakness- S: Speech slurring / difficulty- T: Time to call 9-1-1Stroke risk factors include smoking, obesity, high blood pressure, diets high in saturated fat and/or cholesterol, physical inactivity, atrial fibrillation, carotid artery disease, diabetes, race, and more. Risk of stroke also increases with age for both males and females, and if you have family members who had strokes before age 65. Once you have a stroke, you're also more at risk for having more – all the more reason to focus on prevention.As Lori knows firsthand, it can be scary if you're with someone who could be having a stroke. However, knowing the signs can help with quick treatment - especially important if your loved one is having an ischemic stroke, because the hospital can administer a clot-buster medication. If you or your loved one does have a stroke, recovery is possible: the brain can create new pathways to help you regain your abilities. Topics discussed:- Signs of strokes- Ischemic stroke- Hemorrhagic stroke- Stroke risk factors- High blood pressure- Stroke prevention- Clot bustersTakeaways from this episode:- Remember the acronym F.A.S.T.: Face drooping, Arm weakness, Speech slurring / difficulty – if those are present, Take action by calling 9-11.- Other signs of a stroke include trouble walking or understanding speech, dizziness, loss of balance, and severe headaches without a clear cause.- Make sure your blood pressure is in the health range, which is under 120/80.- Smoking while on birth control pills greatly increases your risk of stroke.- Race is a risk factor of stroke: African Americans have a much higher risk of dying from a stroke than Caucasians.- Women have more strokes and die from strokes more often than men, though they're usually older when they have their first stroke. Resources mentioned in this episode:American Stroke Association:https://www.stroke.org/To suggest a topic, be a guest or to support the podcast, please email Lori@Loriwilliams-seniorservices.com For more senior resources and to sign up to the newsletter, please visit:

Today, it's all about the eyes, which are somewhat the extension of our brain, so treating ANY condition with them can be scary. I've gotten a lot of questions from listeners about dupilumab (Dupixent) and the side effects specifically when it comes to the eyes. So to dive in on this topic, I brought in today's guest, Dr. Roselie Achten, since her PhD focuses on ocular surface disease in atopic dermatitis patients before and during dupilumab treatment. Dr. Roselie Achten is a medical doctor and PhD student at the Department of Dermatology at the University Medical Center Utrecht in the Netherlands, and I am so excited to have her on the show! You can find some of her research findings in the links section below. Have you ever experienced any side effects with your eyes after starting dupilumab? I'd love to hear about it in the comments! In this episode: Stats on how many patients develop Dupixent eye side effects (aka. dupilumab-associated ocular surface disease) Eye symptoms of patients commonly complain about How long does it typically take to develop eye problems from Dupixent? What puts you more at risk for developing Dupixent eye side effects? What are your options if you develop Dupixent eye side effects? Can reducing the use of Dupixent help? Quotes “We were also quite surprised by the fact that the majority of the patients with moderate to severe atopic dermatitis already had characteristics of the ocular surface disease. So of the 70 patients that were analyzed, 90% of them already had characteristics of ocular surface disease before the start of Dupilumab treatment." [11:09] "If patients have these signs and symptoms of dupilumab associated ocular surface disease, we first start with tacrolimus skin ointment for the external eyelids. We also start with ketotifen, which is an antihistamine eye drop... also the artificial tears, it's more for if you experience a dry eye sensation, it could lead to improvement of that symptom for a little time." [17:12] Links Find Dr. Roselie Achten online here Healthy Skin Show ep. 244: How Do Biologic Drugs For Chronic Skin Conditions Work? w/ Heather Zwickey, PhD Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis - ScienceDirect Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis - PMC (nih.gov) Ocular surface disease is common in moderate to severe atopic dermatitis patients - Achten - 2022 - Clinical & Experimental Allergy

Host Nathaniel Chin, MD, starts the new year by discussing modifiable risk factors for Alzheimer's disease, commenting on building healthy lifestyle habits for the new year, and reflecting as Dementia Matters celebrates five years of production. Show Notes “Dementia prevention, intervention, and care: 2020 report of the Lancet Commission” is mentioned at the 4:16 mark. Read the full report on The Lancet's website. Our past episode, “Alcohol and the Brain: One Drink a Day Associated with Brain Shrinkage,” is mentioned at the 5:05 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen.  Our past episode, “Study Finds Air Pollution a Risk Factor For Alzheimer's Disease,” is mentioned at the 5:07 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen. Our past episode, “AARP Study Show Stigma Surrounding Dementia Among Healthcare Professionals And General Public,” is mentioned at the 5:28 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen. As mentioned at the 7:40 mark, learn more about the books The Power of Habit by Charles Duhigg and Atomic Habits by James Clear, on the authors' respective websites. Listen to our past episode, “Impacts of Exercise on Brain Health,” mentioned at the 9:37 mark. Learn about the book, Why Sleep Matters by Matthew Walker, mentioned at the 11:14 mark. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

January is Cervical Cancer Awareness Month. This is just one cancer type that could be avoided when vaccinated against HPV early in life and before exposure to virus-causing cancer. This episode features Dr. Philip Castle who is the director of the Division of Cancer Prevention at the National Cancer Institute. Listen to this powerful conversation on cancer risk reduction for the importance of prevention. To learn more, visit Cervical Cancer Causes, Risk Factors, and Prevention - NCI.

Video for this podcast: https://mehlmanmedical.com/hy-risk-factors/ Main website: https://mehlmanmedical.com/ Instagram: https://www.instagram.com/mehlman_medical/ Telegram private group: https://mehlmanmedical.com/subscribe/ Telegram public channel: https://t.me/mehlmanmedical Facebook: https://www.facebook.com/mehlmanmedical Podcast: https://anchor.fm/mehlmanmedical Patreon: https://www.patreon.com/mehlmanmedical

A new report by the YWCA Halifax, called Hearing Them, details why some youth in this province are vulnerable to exploitation. The goal is to understand and address those risk factors in order to keep children and youth safe. Host Jeff Douglas spoke with Dametre Samuels, Charlene Gagnon and Lila Pavey to learn more.

Headache medicine specialist Rebecca C. Burch, MD, joins us to talk about triptan use in patients with cardiovascular risk factors.Listen in as they clear up confusion about which patients should avoid triptans due to cardiovascular concerns.You'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversitySteven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute and the Lewis and Patricia Dickey Chair in Cardiovascular Medicine Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve UniversityJoseph Scherger, MD, MPH, Family Physician, Primary Care 365, Eisenhower HealthCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.Pharmacist's Letter offers CE credit for this podcast. Log in to your Pharmacist's Letter account and look for the title of this podcast in the list of available CE courses.If you're not yet a Pharmacist's Letter subscriber, find out more about our product offerings at trchealthcare.com. Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

According to the CDC, approximately 96 million Americans have prediabetes which – if left unchecked – often leads to type 2 diabetes. Kim Rose, a dietitian and diabetes expert, explains the causes and symptoms of the disease, and provides insight on how to prevent it and significantly improve your quality of life starting today.If you enjoy this episode, please consider leaving a rating and a review. It makes a huge difference in helping us spread the word about the show.Thanks for listening! To join our #POSITIVITY community or to learn more about Moshe, visit https://linktr.ee/moshepopackTopics:2:15 – Kim explains the difference between type 1 and type 2 diabetes.4:10 – Is sugar always bad for you? And what about “natural” sugar?6:30 – Risk factors for type 2 diabetes and how we can make smarter choices.8:45 – How fiber can help regulate your blood sugar.12:15 – How a lack of sleep can cause an increase of sugar in the bloodstream.16:00 – Why it's so important to get your A1C levels checked early. 21:00 – How Kim thinks we can manage the worldwide obesity crisis.24:00 – Some of the latest medical advances in treating diabetes.

Bloodstream infections (BSIs) acquired in the ICU are potentially preventable. Kyle B. Enfield, MD, FSHEA, FCCM, is joined by Sameer S. Kadri-Rodriguez, MD, MS, to discuss the article, Epidemiology of ICU-Onset Bloodstream Infection: Prevalence, Pathogens, and Risk Factors Among 150,948 ICU Patients at 85 U.S. Hospitals, (Gouel-Cheron A, et al. Crit Care Med. 2022;50:1725-1736). Dr. Kadri-Rodriguez is a critical care and infectious diseases physician at the National Institutes of Health Clinical Center in Bethesda, Maryland. This podcast is sponsored by Sound Physicians.

On the 77th episode of Financial Flossing with host Ross Brannon, the guest is Mark A Cruz. Mark graduated from the UCLA School of Dentistry in 1986 and started a dental practice in Monarch Beach, CA. He has lectured nationally and internationally and is a member of various dental organizations. He was a part-time lecturer at UCLA, a faculty group practice member, and past assistant director of the UCLA Center for Esthetic Dentistry. Listen to this information-packed Financial Flossing episode discussing the risk factors of mouth breathing.     ✔️ Why oral appliance therapy, or CPAP, does not treat the underlying breathing problem.  ✔️ Cranial Facial Development and why this plays a crucial role in research.  ✔️ Why Dr. Cruz is studying the skulls from early medieval periods to understand the airway in facial growth.  ✔️ The difference between mouth breathing and nose breathing and why it matters. ✔️ More information on www.airwaycollaborative.com and the Airway Academy. Connect with Dr. Cruz: Mark A Cruz DDS An Honest Commitment to Excellence 32241 Crown Valley Parkway, Suite 200 Monarch Beach, California 92629 949-661-1006 949-661-9454-fax www.markacruzdds.com www.airwaycollaborative.com www.airwayfocuseddentistry.com markcruz@markacruzdds.com   Learn more about your ad choices. Visit megaphone.fm/adchoices